Schreiner MediPharm Introduces SecuMed Labeling System - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Schreiner MediPharm Introduces SecuMed Labeling System

Equipment and Processing Report

Schreiner MediPharm’s SecuMed pharmaceutical labeling system offers authentication and protection against counterfeiting in a multi-step security concept. The SecuMed labeling system can be customized according to the specific requirements of pharmaceutical manufacturers. The labels can integrate a specific mix of overt, covert, and machine-readable security features. Options include complex holograms, ShiftSecure color-shifting ink, thermo-reactive print (in which colors change at various temperatures), and a covert feature known as LaserSecure, which involves invisible, machine-readable security pigments that can be integrated into all graphic elements and colors. The company will introduce the SecuMed labeling system to the North American market at INTERPHEX 2014.

Source: Schreiner MediPharm

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Equipment and Processing Report,
Click here